PeptideInfo
العربيةGet the app
☰
Skin & AestheticsResearch only

GLOW Blend

GLOW Stack · GHK-Cu + BPC-157

GHK-Cu contributes copper-peptide signaling involved in extracellular matrix remodeling. BPC-157 contributes the soft-tissue repair rationale, with TB-500 present in some formulations. Skin and soft-tissue pathways therefore depend on the actual components, and ingredient findings cannot establish the activity of every mixture.

Not medical advice. Educational reference only.

Route
Injectable / topical, depending on formulation
Storage
Keep at 2–8°C after mixing and use within 28 days.

What is GLOW Blend?

GLOW combines GHK-Cu and BPC-157 in a single preparation; some formulations also contain TB-500. The mixture has no FDA approval. Findings about individual ingredients do not establish efficacy for the combined preparation, and differences in composition matter when interpreting skin and soft-tissue research.

Mechanism of action

GHK-Cu contributes copper-peptide signaling involved in extracellular matrix remodeling. BPC-157 contributes the soft-tissue repair rationale, with TB-500 present in some formulations. Skin and soft-tissue pathways therefore depend on the actual components, and ingredient findings cannot establish the activity of every mixture.

Targets: Skin and soft-tissue repair pathways (component-dependent)

Research indications

  • Skin Repair

    Effective

    Potential skin benefits involve collagen production and support of the skin barrier.

  • Anti-Aging

    Effective

    Investigations suggest possible improvements in fine lines and the texture of skin.

  • Wound Healing

    Moderate

    Experimental applications seek faster closure and repair of skin wounds.

Interactions

  • Medications

    Caution

    Consult your prescriber before combining this compound with any medication.

  • BPC-157

    Compatible

  • NAD+

    Compatible

  • Vitamin D

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

  1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
  2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
  3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
  4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
  5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
  7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
  8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
  9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

What to expect

Week 1–2
Early effects may accompany an adjustment period. Watch for any unwanted reaction as you adapt.
Week 2–4
The principal effects may begin emerging. Follow your clinician’s recommendations for any change in dose.
Week 4–8
Main effects are expected to be apparent at this stage. Review your progress together with your clinician.
Week 8+
Review the outcome with your clinician and decide whether to continue, take a cycle break or adjust the dose. These timings do not establish effectiveness for every compound.

Side effects and safety

  • Bruising, redness or mild soreness where the injection is given
  • Possible allergic response; stop use if you develop hives or a rash
  • Variable individual response; begin with the lowest dose and watch closely for reactions
  • Discuss use with your clinician beforehand and report symptoms that are unusual for you

GLOW Blend: not approved in the US; 503A compounding banned.

Regulatory status

  • US

    Not approved

    FDA — the combined preparation lacks approval and is barred from preparation by 503A compounding pharmacies.

    Rx required
    No
    503A
    Banned
    Telehealth
    N/A

Frequently asked questions

What is GLOW Blend?

GLOW combines GHK-Cu and BPC-157 in a single preparation; some formulations also contain TB-500. The mixture has no FDA approval. Findings about individual ingredients do not establish efficacy for the combined preparation, and differences in composition matter when interpreting skin and soft-tissue research.

Which applications are being investigated?

Investigations focus on skin repair, anti-aging, wound healing. The indication ratings summarize proposed applications and do not establish a study design or an approved treatment. Discuss any intended use with a qualified clinician.

Which dosing schedules are discussed?

There is no single numeric dose for every formulation. Amounts depend on the preparation, and the route can be injectable or topical. Each component contributes its own half-life. A low initial amount and a later titrated amount are the two non-numeric schedules; both leave frequency to the protocol and allow the route to vary. Consult a clinician about the actual preparation.

What should I know about adverse effects?

Adverse reactions can differ with the amount administered, the route and individual sensitivity. Human studies do not fully characterize the compound-specific adverse-effect profile. Watch for local injection reactions and possible allergy, and discuss symptoms with a qualified clinician.

References

  1. Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract (2018)

  2. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes (2018)